Here, leveraging the tropism of facultative anaerobic bacteria to localize and propagate in the hypoxic tumor, an optogenetically engineered Escherichia coli Nissle 1917 strain conjugated with murine STING agonist (EcN<sub>flaB</sub>@UPD) was developed for cancer-specific immunotherapy. Here, STING1 is linked to neoplasm.